Alisporivir (

INN Inns are generally establishments or buildings where travelers can seek lodging, and usually, food and drink. Inns are typically located in the country or along a highway; before the advent of motorized transportation they also provided accommo ...

), or Debio 025, DEB025, (or UNIL-025) is a

cyclophilin Cyclophilins (CYPs) are a family of proteins named after their ability to bind to ciclosporin (cyclosporin A), an immunosuppressant which is usually used to suppress rejection after internal organ transplants. They are found in all domains of l ...

inhibitor. Its structure is reminiscent of, and synthesized from

ciclosporin Ciclosporin, also spelled cyclosporine and cyclosporin, is a calcineurin inhibitor, used as an immunosuppressant medication. It is a natural product. It is taken orally or intravenously for rheumatoid arthritis, psoriasis, Crohn's disease ...

. It inhibits

cyclophilin A Peptidylprolyl isomerase A (PPIA), also known as cyclophilin A (CypA) or rotamase A is an enzyme that in humans is encoded by the ''PPIA'' gene on chromosome 7. As a member of the peptidyl-prolyl cis-trans isomerase (PPIase) family, this protein ca ...

. Alisporivir is not immunosuppressive. It is being researched for potential use in the treatment of hepatitis C. It has also been investigated for

Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy that primarily affects boys. Muscle weakness usually begins around the age of four, and worsens quickly. Muscle loss typically occurs first in the thighs and pelvis follow ...

and may have therapeutic potential in Alzheimer's disease. Alisporivir is under development by

Debiopharm Debiopharm is a family-owned biopharmaceutical company active in drug development and manufacturing of proprietary drugs, diagnostics, and investments, headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.

for Japan and by

Novartis Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, Massachusetts, United States (global research).name="novartis.com">https://www.novartis.com/research-development/research-loc ...

for the rest of the world (licence granted by

) since February 2010.

References

{{reflist Antiviral drugs Peptides Orphan drugs